Edition:
United Kingdom

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.28USD
14 Dec 2017
Change (% chg)

$-0.08 (-0.60%)
Prev Close
$13.36
Open
$13.41
Day's High
$13.50
Day's Low
$13.27
Volume
326,536
Avg. Vol
241,904
52-wk High
$14.87
52-wk Low
$10.30

Select another date:

Wed, Nov 1 2017

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Innoviva reports Q3 adj earnings $0.31/shr

* Innoviva reports third quarter 2017 financial results and provides business updates

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

Sept 18 GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

BRIEF-Innoviva prices offering of $175 mln of 2.50 pct convertible senior notes

* Innoviva Inc. prices offering of $175 million of 2.50 pct convertible senior notes Source text for Eikon: Further company coverage:

BRIEF-Innoviva proposes $175 mln offering of convertible senior notes

* Innoviva announces proposed offering of $175 million of convertible senior notes

BRIEF-Innoviva Q2 adjusted earnings per share $0.35

* Innoviva reports strong second quarter 2017 financial results

Select another date: